Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial (Q43777913)
Jump to navigation
Jump to search
scientific article published on 18 August 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial |
scientific article published on 18 August 2003 |
Statements
1 reference
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial (English)
1 reference
1 reference
1 reference
Christopher B Granger
1 reference
Kenneth W Mahaffey
1 reference
Witold Ruzyllo
1 reference
Pierre Theroux
1 reference
Thomas G Todaro
1 reference
W Douglas Weaver
1 reference
Thomas G Filloon
1 reference
Scott Rollins
1 reference
Jose C Nicolau
1 reference
COMMA Investigators
1 reference
18 August 2003
1 reference
1 reference
Identifiers
1 reference